July 24, 2024:

Daniel Isaac, DO, an Assistant Professor in the Division of Hematology and Oncology at Michigan State University College of Human Medicine, has been appointed to represent Michigan State University on the Big Ten Cancer Research Consortium Steering Committee.

The Steering Committee is composed of one researcher from each Big Ten CRC member institution and meets regularly to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC.

Dr. Isaac received his DO from Edward Via College of Osteopathic Medicine at Virginia Tech. He completed his residency in internal medicine at William Beaumont Hospital in Royal Oak, Mich. Dr. Isaac completed his fellowship in Hematology/Oncology at Michigan State University.

Michigan State University Cancer Research faculty and trainees span the Colleges of Human Medicine, Osteopathic Medicine, Veterinary Medicine, Natural Sciences, Nursing, and Engineering. MSU has multiple integrated scientific disciplines with one common goal: to make discoveries and translate those discoveries for cancer patients.

Dr. Isaac’s clinical work and research at MSU is focused on breast and genitourinary cancers. His current work is focused on molecular biomarkers in prostate cancer as well as addressing disparities in prostate cancer.

“The Big Ten CRC’s model of academic physicians collaborating at the grassroots level to create meaningful protocols is truly unique,” said Dr. Isaac. “Through this collaboration, we’re raising important research questions and answering them in a systematic fashion.”

In his new leadership role, Dr. Isaac hopes to engage more physicians at each institution, especially younger faculty, with the goal of increasing mentorship opportunities within the consortium.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.